Related Experiment Video

Updated: May 10, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

The Role of Uric Acid in the Pathogenesis of Heart Failure With Preserved Ejection Fraction

Jie Tan1, Jiahan Ke, Xiaohan Qiu

  • 1From the Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Cardiology in Review
|May 8, 2026
PubMed

Insights

Elevated uric acid (UA) is a significant risk factor for heart failure with preserved ejection fraction (HFpEF). Lowering UA may offer therapeutic benefits for HFpEF patients.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Renal Physiology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is increasing due to aging and comorbidities like hypertension and diabetes.
  • Elevated serum uric acid (UA), a product of purine metabolism, is linked to metabolic syndrome and identified as an independent risk factor for HFpEF.
  • UA contributes to HFpEF pathophysiology by promoting oxidative stress, inflammation, and endothelial dysfunction.

Purpose of the Study:

  • To review the epidemiological link between UA and HFpEF.
  • To elucidate the mechanisms by which UA influences HFpEF development and progression.
  • To assess the potential of urate-lowering therapies in managing HFpEF.

Main Methods:

  • Systematic review of epidemiological studies.
  • Analysis of preclinical and clinical data on UA's role in HFpEF.
  • Evaluation of evidence for urate-lowering agents in HFpEF.

Main Results:

  • Epidemiological data confirm a strong association between high UA levels and HFpEF incidence, progression, and prognosis.
  • UA directly exacerbates HFpEF through oxidative stress, inflammasome activation, and microvascular damage.
  • Urate-lowering therapies show promise for HFpEF treatment.

Conclusions:

  • Serum UA is a critical factor in HFpEF pathogenesis.
  • Management of UA levels is crucial for HFpEF patients.
  • Further research into pharmacological interventions targeting UA is warranted.

Keywords:
heart failure with preserved ejection fractionserum uric acidurate-lowering therapy

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...